Core Viewpoint - The company, Fengshan Group, clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking it to the "solid-state battery" concept [1] Business Operations - The company primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a very small portion of sales, accounting for only 0.01% of the consolidated revenue by mid-2025 [1] - The collaboration with Tsinghua University, led by Professor Zhang Qiang, is at an early research and development stage, with a small contract amount and a long project timeline extending to December 31, 2028 [1] Research and Development - The research project commissioned by the company is not the same as the significant research results recently published by Professor Zhang's team [1] - There is considerable uncertainty regarding the future research outcomes and their commercialization [1]

Core Viewpoint - Fengshan Group (603810.SH) clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking the company to the "solid-state battery" concept [1] Business Operations - The company emphasizes that its main operations have not changed, and its subsidiary Fengshan Quannuo primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are projected to represent only 0.01% of the company's consolidated revenue [1] Research and Development - The recent important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is expected to last until December 31, 2028, indicating significant uncertainty regarding future research outcomes and commercialization [1]

Core Viewpoint - Fengshan Group (603810.SH) clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking the company to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary Fengshan Quannuo primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to represent only 0.01% of the company’s consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028, indicating significant uncertainty regarding future research outcomes and commercialization [1]

Core Viewpoint - The company, Fengshan Group (603810.SH), clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite recent media reports linking it to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a relatively small portion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to account for only 0.01% of the company's consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]

Core Viewpoint - The company clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking it to the "solid-state battery" concept [1] Business Operations - The company's main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a relatively small portion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to account for only 0.01% of the company's consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the company's commissioned research and development project [1] - The collaboration with Tsinghua University is currently in the preliminary research and development phase, with a small contract amount, and the technology development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]

Core Viewpoint - The company, Fengshan Group, clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite recent media speculation linking it to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, the sales revenue from sodium-ion electrolytes is expected to represent only 0.01% of the company's consolidated operating income [1] Research and Development - The recent important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]

Group 1 - The company announced the early termination of the share reduction plan by shareholders and senior management [5] - Before the reduction plan, shareholder Gu Cuiyue held 1,342,800 shares (0.81% of total shares), while other key personnel held varying amounts [2] - The actual share reduction included Gu Cuiyue reducing 230,500 shares (0.14%), Vice President Shan Yongxiang reducing 313,000 shares (0.19%), and CFO Wu Hancun reducing 167,400 shares (0.10%) [3][4] Group 2 - The company signed a technical development contract with Tsinghua University for research on sodium-ion and solid-state lithium-ion battery electrolytes, with significant uncertainty regarding the outcomes [8][9] - The contract is in the early research phase and is not expected to impact the company's main business or 2025 financial performance significantly [8][10] - The main products of the company's subsidiary, Fengshan Quannuo, are sodium-ion and lithium-ion battery electrolytes, with limited revenue and intense market competition [10]